Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization

2019 ◽  
Vol 44 (6) ◽  
pp. 652-659 ◽  
Author(s):  
Priyal P Fadadu ◽  
Anthony J Mazzola ◽  
Corey W Hunter ◽  
Timothy T Davis
Keyword(s):  
Systematic Review ◽  
Growth Factors ◽  
Platelet Rich Plasma ◽  
White Cell Count ◽  
Pain Medicine ◽  
Inclusion Criteria ◽  
Separation Systems ◽  
Platelet Concentration ◽  
Large Heterogeneity ◽  
Promising Treatment

Platelet-rich plasma (PRP) has become increasingly popular in pain medicine with hopes of becoming a safe, effective alternative to routine treatments. However, given its autologous nature, PRP injectate may differ depending on the specific manufacturer and protocol. Currently, there is no standardization of reporting protocol. This systematic review compiles and standardizes values on PRP preparation and final product composition of platelets, white cell count, and growth factors for ease of comparison. On review of 876 studies, 13 studies were selected according to our inclusion criteria. Data from 33 PRP systems and protocols were extracted and standardized. Overall, PRP final product concentrations as well as PRP preparation protocols varied widely between systems. However, platelet concentration was directly correlated with both volume of blood collected and device centrifugal force. In conclusion, there is a large heterogeneity between PRP separation systems that must be resolved for proper study of this promising treatment.

scholarly journals Non-operative orthobiologic use for rotator cuff disorders and glenohumeral osteoarthritis: A systematic review

2020 ◽  
pp. 1-16
Author(s):  
David M. Robinson ◽  
Christine Eng ◽  
Steven Makovitch ◽  
Joshua B. Rothenberg ◽  
Stephanie DeLuca ◽  
...  
Keyword(s):  
Systematic Review ◽  
Rotator Cuff ◽  
Cohort Studies ◽  
Randomized Clinical Trials ◽  
Platelet Rich Plasma ◽  
Inclusion Criteria ◽  
Serious Adverse Events ◽  
Bias Risk ◽  
Glenohumeral Osteoarthritis ◽  
Functional Outcome Measures

BACKGROUND: Shoulder pain from rotator cuff pathology and glenohumeral osteoarthritis is a common entity encountered in musculoskeletal practices. Orthobiologic agents are being increasingly used as a treatment option and understanding their safety and efficacy is necessary. OBJECTIVE: To systematically evaluate the available evidence for orthobiologic use in rotator cuff and glenohumeral pathology. METHODS: A systematic review was undertaken following PRISMA guidelines. Randomized clinical trials (RCTs) and prospective cohort studies evaluating non-operative treatment with prolotherapy, platelet-rich plasma (PRP), or medicinal signaling cells (MSCs) for rotator cuff pathology and glenohumeral osteoarthritis were included. Bias risk assessments used were the Cochrane tool and Newcastle-Ottawa score. RESULTS: The search yielded 852 potential articles, of which 20 met the inclusion criteria with a breakdown of 5 prolotherapy, 13 PRP, and 2 MSC. Sixteen studies were RCTs and 4 were cohort studies. Six studies were deemed “low risk of bias or good quality”. Efficacy results were mixed, and no serious adverse events were reported from orthobiologic treatment. CONCLUSIONS: Orthobiologics offer a relatively safe management option with inconclusive evidence for or against its use for rotator cuff pathology. No studies on glenohumeral osteoarthritis met the inclusion criteria. Adoption of standardized preparation reporting and consistent use of functional outcome measures is imperative for future studies to consider.

Concentrations of Blood Components in Commercial Platelet-Rich Plasma Separation Systems: A Review of the Literature

2018 ◽  
Vol 47 (2) ◽  
pp. 479-487 ◽  
Author(s):  
Bart W. Oudelaar ◽  
Joost C. Peerbooms ◽  
Rianne Huis in ‘t Veld ◽  
Anne J.H. Vochteloo
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Platelet Rich Plasma ◽  
Therapeutic Option ◽  
Transforming Growth Factor Β1 ◽  
Future Research ◽  
Cochrane Central Register ◽  
Blood Components ◽  
Separation Systems

Background: Platelet-rich plasma (PRP) has proven to be a very safe therapeutic option in the treatment of tendon, muscle, bone, and cartilage injuries. Currently, several commercial separation systems are available for the preparation of PRP. The concentrations of blood components in PRP among these separation systems vary substantially. Purpose: To systematically review and evaluate the differences between the concentrations of blood components in PRP produced by various PRP separation systems. Study Design: Systematic review. Methods: MEDLINE/PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE were searched for studies that compared the concentrations of blood components and growth factors in PRP between various separation systems and studies that reported on the concentrations of blood components and growth factors of single separation systems. The primary outcomes were platelet count, leukocyte count, and concentration of growth factors (eg, platelet-derived growth factor–AB [PDGF-AB], transforming growth factor–β1 [TGF-β1], and vascular endothelial growth factor [VEGF]). Furthermore, the preparation protocols and prices of the systems were compared. Results: There were 1079 studies found, of which 19 studies were selected for inclusion in this review. The concentrations of platelets and leukocytes in PRP differed largely between, and to a lesser extent within, the studied PRP separation systems. Additionally, large differences both between and within the studied PRP separation systems were found for all the growth factors. Furthermore, preparation protocols and prices varied widely between systems. Conclusion: There is a large heterogeneity between PRP separation systems regarding concentrations of platelets, leukocytes, and growth factors in PRP. The choice for the most appropriate type of PRP should be based on the specific clinical field of application. As the ideal concentrations of blood components and growth factors for the specific fields of application are yet to be determined for most of the fields, future research should focus on which type of PRP is most suitable for the specific field.

Unactivated platelet leukocyte autoplasma in the treatment of non scarring alopecia

2016 ◽  
Vol 19 (6) ◽  
pp. 369-377
Author(s):  
G. A Ragimov ◽  
O. Yu Olisova ◽  
Kseniya G. Egorova
Keyword(s):  
Growth Factors ◽  
Clinical Cure ◽  
Clinical Observation ◽  
Platelet Rich Plasma ◽  
White Blood Cells ◽  
Treatment Method ◽  
Hair Follicles ◽  
Scarring Alopecia ◽  
Platelet Concentration

The literature review of the cellular functioning mechanisms of the hair follicles, the role of stem cells in the life cycle of the hair, the major effects of growth factors are presented. Authors, patented treatment method of non scarring alopecia is described. The technology ofpreparation and method of use of unactivated platelet leukocyte autoplasma in various forms of alopecia are described. Own clinical observation of 60 patients with non scarring alopecia and results of their unactivated platelet leukocyte autoplasma are presented. 80% of patients had a clinical cure. Investigations of platelet concentration, white blood cells and growth factors in platelet-rich plasma and platelet leukocyte unactivated autoplasma were performed. The results are shown in the article.

scholarly journals Treatment of venous ulcers with growth factors: systematic review and meta-analysis

2019 ◽  
Vol 72 (1) ◽  
pp. 200-210 ◽  
Author(s):  
Magali Rezende de Carvalho ◽  
Isabelle Andrade Silveira ◽  
Beatriz Guitton Renaud Baptista de Oliveira
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Growth Factors ◽  
Growth Factor ◽  
Randomized Clinical Trials ◽  
Platelet Rich Plasma ◽  
Meta Analysis ◽  
Intervention Group ◽  
Complete Healing ◽  
Venous Ulcers

ABSTRACT Objective: To identify evidence about the effects of growth factor application on venous ulcer healing. Method: Systematic review and meta-analysis, including Randomized Clinical Trials. Searches: Ovid MEDLINE, EMBASE, CINAHL, Cochrane CENTRAL, LILACS, Web of Science, Digital Library of Theses and Dissertations; Google Scholar and list of references. Results: 802 participants were recruited from the 10 included studies: 472 in the intervention group (growth factors) and 330 as control. The relative risk for the complete healing outcome was 1.06 [95% CI 0.92-1.22], p = 0.41. Participants who received Platelet-Rich Plasma and Epidermal Growth Factor showed a slight tendency to achieve complete healing, but without statistical relevance (p <0.05). Most of the studies were classified as moderate risk of bias. Conclusion: The effect of the application of growth factors for complete healing in venous ulcers is not clear, and clinical trials with methodological quality are required for more accurate recommendations.

Use of autologous platelet-rich plasma in trichology

2021 ◽  
pp. 30-32
Author(s):  
A. V. Gismieva
Keyword(s):  
Growth Factors ◽  
Platelet Rich Plasma ◽  
Promising Treatment ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

The article is of a review nature and contains up-to-date information on the application autologous platelet-rich plasma in trichology. The use of autologous platelet-rich plasma is a promising treatment. The application on this technique is to improve and accelerate the processes caused by the stimulating growth factors contained in platelets.

scholarly journals Effects of Antiplatelet and Nonsteroidal Anti-inflammatory Medications on Platelet-Rich Plasma: A Systematic Review

2020 ◽  
Vol 8 (4) ◽  
pp. 232596712091284 ◽  
Author(s):  
Christopher Frey ◽  
Peter Chia Yeh ◽  
Prathap Jayaram
Keyword(s):  
Systematic Review ◽  
Growth Factors ◽  
Growth Factor ◽  
Platelet Rich Plasma ◽  
Antiplatelet Agent ◽  
Cochrane Library ◽  
Dependent Manner ◽  
Growth Factor Release ◽  
Anti Inflammatory ◽  
Factor Release

Background: Platelet-rich plasma (PRP) has wide applications in orthopaedic care. Its beneficial effects are attributed to the growth factor profile from the platelet secretome. In theory, these effects would be diminished by medications that inhibit platelet activation and/or the subsequent release of growth factors. Purpose: To determine whether commonly used antiplatelets, nonsteroidal anti-inflammatory drugs (NSAIDs), or anticoagulant medications affect platelet growth factor release in PRP. Study Design: Systematic review; Level of evidence, 2. Method: A systematic review of the literature related to antiplatelet, anti-inflammatory, and anticoagulant drugs was performed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We used the Downs and Black objective quality scoring system. The literature search consisted of PubMed and Cochrane Library databases. Search terms consisted of 1 item selected from “platelet-rich plasma,” “platelet-derived growth factor,” and “platelet-rich plasma AND growth factor” combined with 1 item from “antiplatelet,” “aspirin,” “anticoagulant,” and “NSAID.” Only studies published within the past 25 years were included. Results: A total of 15 studies met the inclusion criteria: 7 studies detected no significant decrease in growth factors or mitogenesis, whereas 6 detected a decrease with antiplatelet agents, 1 detected mixed results with an antiplatelet agent, and 1 had mixed results with an antiplatelet agent/vasodilator. In terms of PRP activation, all 3 studies assessing collagen, the 2 studies analyzing adenosine diphosphate alone, and the 1 study investigating arachidonic acid found a decrease in growth factor concentration. Conclusion: Antiplatelet medications may decrease the growth factor release profile in a cyclooxygenase 1– and cyclooxygenase 2–dependent manner. Eight of 15 studies found a decrease in growth factors or mitogenesis. However, more studies are needed to comprehensively understand antiplatelet effects on the PRP secretome.

scholarly journals The Use of Platelet-Rich Plasma for Treatment of Tenodesmic Lesions in Horses: A Systematic Review and Meta-Analysis of Clinical and Experimental Data

Animals ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 793
Author(s):  
Chiara Montano ◽  
Luigi Auletta ◽  
Adelaide Greco ◽  
Dario Costanza ◽  
Pierpaolo Coluccia ◽  
...  
Keyword(s):  
Systematic Review ◽  
Platelet Rich Plasma ◽  
Meta Analysis ◽  
Inclusion Criteria ◽  
Control Groups ◽  
Definitive Evidence ◽  
Dichotomous Data ◽  
And Control ◽  
Risk Ratios

The use of platelet-rich plasma (PRP) to enhance tenodesmic lesion healing has been questioned over the years. The aim of this study was to evaluate current literature to establish the effectiveness of PRP for treating tenodesmic lesions through a systematic review, in accordance with the PRISMA guidelines, and a meta-analysis. Studies comparing PRP with placebo or other treatments for horses with tenodesmic injuries or evaluated PRP effect on tendon and ligament explants were included. Outcomes were clinical, ultrasound, histologic, molecular evaluation, and adverse effects. Two authors independently extracted data and assessed each study’s risk of bias. Treatment effects were evaluated using risk ratios for dichotomous data, together with 95% CI. Data were pooled using the random-effects model. The quality of the evidence for each outcome was assessed using GRADE criteria. Twenty-four trials met inclusion criteria for systematic review, while fifteen studies were included in the meta-analysis. Results showed no significant differences in the outcomes between PRP and control groups. Finally, there is no definitive evidence that PRP enhances tendons and ligaments healing. Therefore, there is a need for more controlled trials to draw a firmer conclusion about the efficacy of PRP as a treatment for tenodesmic lesions in the horse.

Quality assessment of platelet rich plasma during anti-platelet therapy

Perfusion ◽  
2007 ◽  
Vol 22 (1) ◽  
pp. 41-50 ◽  
Author(s):  
Chad W Smith ◽  
Robert S Binford ◽  
David W Holt ◽  
David P Webb
Keyword(s):  
Growth Factors ◽  
Acetylsalicylic Acid ◽  
Platelet Rich Plasma ◽  
Surgical Wound ◽  
Platelet Function Test ◽  
Wound Site ◽  
Clopidogrel Bisulfate ◽  
Anti Platelet Therapy ◽  
Function Test ◽  
Platelet Concentration

Platelet rich plasma (PRP) is being used with increased frequency in many surgical procedures for its known benefits of accelerated surgical wound site healing. Speculations in its efficacy in the presence of anti-platelet therapy have been proposed. To aid in defining a quality platelet rich plasma product in the presence of acetylsalicylic acid (ASA) and Plavix (clopidogrel bisulfate), we investigated three (3) groups (n=18) of cardiac surgical patients receiving PRP. Platelet function test, platelet concentration, and quantification of growth factors (PDGF-bb and TGF-b1) were evaluated. Results showed no statistical evidence of decreased growth factors delivered to the surgical wound site in the presence of acetylsalicylic acid (ASA) and/or Plavix (clopidogrel bisulfate). Evidence in this pilot study supports the use of PRP for patients receiving Plavix and aspirin therapy without compromising the quantity of specific growth factors delivered to a wound site. Perfusion (2007) 22, 41—50.

scholarly journals PRP and PRF—Subgroups and Divisions When Used in Dentistry

2021 ◽  
Vol 11 (10) ◽  
pp. 944
Author(s):  
Paulina Pietruszka ◽  
Izabela Chruścicka ◽  
Irena Duś-Ilnicka ◽  
Anna Paradowska-Stolarz
Keyword(s):  
Systematic Review ◽  
Growth Factors ◽  
Personalized Medicine ◽  
Platelet Rich Plasma ◽  
Platelet Rich Fibrin

Blood derivates, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), are autogenous sources of many growth factors that are involved in the healing and regeneration of tissues, and for this reason, are used in dentistry treatments. This fact also contributes to the growing interest in these biomaterials in regenerative personalized medicine. The multitude of platelet-rich forms creates many possibilities for their use. This semi-systematic review describes and compares the methods of obtaining properties and potential uses of these materials in personalized treatments.

Sign in / Sign up

Export Citation Format

Share Document